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Introduction
Sub-Saharan Africa, home to over 10% of  the world’s 
population, remains the worst HIV-affected region in the 
world. In fact, this geographical area is home to approximately 
70% of  all people living with HIV (PLHIV) globally1. While 
the number of  people newly diagnosed with HIV is falling, 
both HIV and AIDS remain major public health challenges 
in Nigeria, the country with the second largest HIV epidemic 
in the world2. Findings from the 2014 HIV National Sentinel 
Survey showed that Nigeria, Africa’s most populous nation 
with a population of  186 million, had an HIV prevalence of  
3.0%.ranging from 0.9% to 15.4% across different zones2,3. 
Furthermore, thissurvey showed that 1.6 million women 
were living with HIV compared with 1.4 million men2,3. The 
magnitude of  the HIV epidemic, and the complexity of  its 
chronicity, however, represent major challenges to healthcare 
delivery systems in both resource-rich and resource-
constrained settings4. In resource-constrained settings,in 
which healthcare services are not well developed, there are 
two major challenges faced by anti-retroviral therapy (ART) 
programs:poor adherence to treatment and defaulting from 
treatment5.
Adherence has been difficult to sustain for patients receiving 
highly active anti-retroviral therapy (HAART) across the 
globe6. The meanrate of  adherence to ART is approximately 
70%, despite the fact that long-term viral suppression requires 
near-perfect adherence7. On the other hand, poor adherence 
compromises the efficacy of  treatment, making this a 
critical public health issue8. As one of  the major predictors 
of  progression to AIDS and death after CD4 count, poor 
adherence is also associated with the development of  drug-
resistant viral strains and virological failure7,9,10.The results 
of  a 2006 meta-analysis of  ART adherence showed that, on 
average, 23% of  patients in studies from sub-Saharan Africa 
did not achieve adequate adherence, with the proportion of  
non-adherent patients ranging from 2% to 70%11.
Rates and predictors of adherence and retention for 
antiretroviral therapy among HIV-positive adults in 
Enugu, Nigeria
Onyinye Hope Chime1,2,Edmund Onyemaechi 
Ndibuagu1,2,Chinonyelu Jennie Orji1
1. Department of  Community Medicine, Enugu State University Teaching Hospital, Enugu, Nigeria
2. Department of  Community Medicine, Enugu State University College of  Medicine, Enugu, Nigeria
Abstract
Background
HIV infection and AIDS are majorpublic health challenges in Nigeria, a country with one of  the highest rates of  new infection in 
sub-Saharan Africa and the second largest HIV epidemic in the world.Non-adherence to medication and defaulting from treatment are 
the two major challenges faced by anti-retroviral therapy (ART) programs in resource-constrained settings. This study was undertaken 
to determine the rate and predictors of  adherence to medication and retention among people living with HIVin Enugu State, Nigeria.
Methods
This was a cross-sectionalretrospective study conducted among adults living with HIV(PLHIV) receiving ARTs in eightcomprehensive 
health facilities in Enugu, Nigeria. We used self-reported adherence and recorded clinic visits to assess adherence and retention, 
respectively. Descriptive statistics (frequencies, proportions, mean and standard deviation) and regression analysis were then conducted 
to identify the association between adherence, retention and demographic and health-related factors. 
Results
The mean age of  respondents was 38.5±9.8 years. Predictors of  good adherence to medication includedbeing male(adjusted odds ratio 
[AOR]:2.08; 95% confidence interval [CI]:1.12–3.85), having been on anti-retroviral medications for more than 5 years (AOR:1.92; 
95% CI: 1.17–3.16), the non-consumption of  alcohol(AOR: 3.67; 95% CI: 2.01–6.70),not usingtraditional medicine (AOR: 2.76; 
95% CI:1.33–5.73) and having a baseline CD4count exceeding 500 cells/μl (AOR: 5.67; 95% CI: 1.32–24.32).Adequate retention 
was predicted by being resident in the urban area (AOR: 1.90; 95% CI: 1.17–3.06). Being away from home (41.8%) and forgetfulness 
(35.0%) were reported as the major reasons for missing medication.
Conclusion
The rates of  adherence and retention found in this study were similar to those reported forother resource-limited settings. Health 
education and behavioural modification interventions should be intensified to reduce the consumption of  alcohol and the use of  
traditional medicine by people living with HIV. Identifying other factors may help to design effective strategies to ensure that people 
living with HIV adhere to their medications and remain in care.
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Despite the widely acknowledge scale-up in the use of  
ARTs, retaining patients in care remains a well-documented 
global challenge and has undermined efforts to enhance 
treatment outcomes12,13. Patient retention is a function of  
attrition which includes deaths, patients who are lost-to-
follow-up (LTFU) and those who stop treatment.LTFU is 
the most common cause of  attrition, followed by death12.
Furthermore, LTFU has been shown to contribute to poorer 
health outcomes for patients, constitutes a serious form of  
resource wastage, and can promoteHIV drug resistance14. In 
2007, a meta-analysis of  ART programs in Africa showed 
a retention of  approximately 60% and 76% of  patients on 
ART at the end of  2 years and 3 years, respectively15. Similar 
findings were reported in an updated meta-analysis of  39 
cohorts from sub-Saharan Africa in 201112.
Many barriers to adherence are common to both developed 
and developing settings, such as fear of  disclosure. Other 
barriers are unique to studies conducted in the developing 
world, such as financial constraints (cost of  drugs and/or 
transport) and others, such as stigma, a feeling of  being 
healthy and forgetfulness5,16,17. Other factors can also 
make it more difficult for patients to adhere to treatment, 
includingmental illness, the complexity of  drug regimes, 
the side effects of  medication, active alcohol use, substance 
abuse and the non-disclosure of  HIV status6,18,19. Factors 
such as increased duration on ART, male gender, an age of  
less than 15 years and a World Health Organization (WHO) 
classification of  stage III and IV have been shown to be 
significantly associated with retention20. Based on a study 
population in south-eastern Nigeria, Onoka et al. reported 
that being male, having a CD4 countless than 200/μl and 
being treated by a public hospitalwere good predictors of  
retention-in-care20. In another study, Eguzo et al. found 
that baseline CD4 count, the year of  enrolment and drug 
combination were significant predictors of  retention14.
With the positive strides already gained in the fight against 
AIDS over recent years, the paradigm of  HIV care has now 
shifted to theestablishment of  a continuum of  care among 
PLHIV. Although research has shown that adequate ART 
adherence rates can be achieved in resource-poor settings11, 
there are concerns that adherence to ART in such settings 
may decline as access to treatment increases10. The present 
studycollaborated with several healthcare facilities within 
Enungu State Nigeria and aimed to investigate adherence 
to medication and retention among PLHIV. Findings 
from this study will aid the planning and implementation 
of  intervention programs so that we can scale-up ART 
adherence and retention of  PLHIV in Enugu State Nigeria. 
Methods
Study setting
Enugu state is one of  the five states in south-eastern 
Nigeria, with a population of  3,257,298 people22, three 
senatorial zones and 17 local government areas (which serve 
as administrative units for the state). The ART program 
was introduced into this state in 2004 and first began to 
provide free drugs to patients in 2006. In Enugu state, ART 
services are now offered in 21 comprehensive ART sites, in 
both public and private health institutions. This study was 
conducted in eight comprehensive health facilities in Enugu 
state: Mother of  Christ Specialist Hospital, University of  
Nigeria Teaching Hospital, Annunciation Specialist Hospital, 
Enugu State University Teaching Hospital, Nsukka District 
Hospital, Bishop Shanahan Hospital, Udi District Hospital 
and General Hospital Nsukka.
Study design, population and sampling
This study combined both cross-sectional and retrospective 
study designs involving PLHIV who accessed care in 
comprehensive health facilities in Enugu state. We included 
all PLHIV that were over 18 years of  age and had been 
onHAART for at least 1 year prior to the study commencing. 
We excluded patients who refused to provide consent, whose 
records were incomplete or missing, or who were in HIV 
clinical stage III or IV and in a generally poor clinical state at 
presentation, usually with complicated AIDS-defining illness.
The minimum sample size for the study was determined 
based on the expected proportion of  adherence to ART 
among PLHIV in a previous study (75%)5; the calculations 
involved the use of  Fisher’s statistical formula23. However, 
in order to increase the validity of  the study, a sample 
size of  840 was used, with a relative precision of  5% and 
a confidence interval of  95%. We then compiled a list of  
patients attending ART clinics using files from the medical 
records department of  the eight selected health facilities. We 
used this data to then determine the sampling frame for the 
study.Theeight facilities were selected proportionately from 
the three senatorial zones. The sample size was proportionally 
allocated to the facilities based on their patient load. A 
systematic sampling technique was then used to select the 
study participants as they presented for their routine clinic 
visits.
Data collection
The study lasted for 6 weeks (August to September 2016).
Data was collected from study participants using two 
approaches; a pre-tested semi-structured interviewer-
administered questionnaire designed by the principal 
researcher, and medical records. The questionnaire contained 
a section relating to socio-demographic information and 
another section on self-reported adherence. Additional 
questions were developed to acquire responses peculiar 
to this study such as disclosure, social habitsand theHIV 
status of  partner.We reviewed the medical records of  each 
participant to ascertain retention over a period of  1 year 
prior to the study. Routine health data were extracted from 
medical records, includingthe year of  HIV diagnosis, the 
duration on HAART, the type of  regimen, dosing frequency 
and the regularity of  routine clinic visits. The questionnaire 
was pretested among 42 randomly selected PLHIV from 
a health facility in Agbani district, which was not selected 
for the main study. Ambiguities or deficiencies in the study 
instruments were then revised. Ethical approval was obtained 
from the Health Research and Ethics Committee of  Enugu 
State University Teaching Hospital, Enugu. The study was 
also approved by theState Ministry of  Health and the Heads 
of  the health facilities involved. Written consent was secured 
from each participant and anonymity was assured.
Measurement of variables
We used the pharmacy records, regimen type and dosing 
frequency to estimate the total number of  doses expected 
and delivered within a 1-month period. In order to determine 
self-reported adherence, we asked our participants the 
following question:‘How many pills were you unable to 
take in the past 28 days?’ Self-reported adherence was then 
ascertained by calculating the proportion (%) of  medication 
(pills) taken over 28 days divided by the number of  pills 
prescribed within the same period. In this study, adherence 
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WHO definitions24.
Retention was assessed using the medical records of  
each participantover a period of  1 year prior to the study 
commencing. Participants who were absent from treatment 
for at least 90 days (3 months) from the last given refill or 
appointment date were considered LTFU and scored as ‘0’ 
was classified as either good or poor. Good adherence 
was scored as ‘1’ while poor adherence was scored as ‘0’. 
Participants who achieved an adherenceof  less than 95% 
were classified as having poor adherence, while those withan 
adherence of  95% and abovewere classified as having good 
adherence; these classifications were based on established 
Table 1. Socio-demographic characteristics of respondents (N=840)
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while those that reported at least once within 3 months were 
scored as ‘1’20. The quarterly visits (four visits annually) 
were summated over the year. For the purpose of  this study, 
retention was categorizedas either adequate or inadequate. 
Adequate retention was scored as‘1’ while inadequatewas 
scored as‘0’. Participants with a total of  four visits were 
categorized as having adequate retention while those 
who made less than fourvisits were categorized as having 
inadequate retention.To avoid recall bias, we extracted this 
information from thehospital records of  each participant.
Data analysis
Data cleaning and editing were performed manually and were 
designed todetect omissions and ensure uniform coding.
Data entry and analysis were performed using the Statistical 
Package for Social Sciences (SPSS) version 22. Frequencies 
and proportions were derived for categorical variables 
and analysed using the chi-square test and Student’s t-test. 
Multivariate analysis, using binary logistic regression,was 
also used to predict the probability of  occurrence for each 
outcome variable. Results are reported asodds ratios and95% 
confidence intervals; the level of  significance was set to 0.05.
Variables showing a P-value <0.2 in the bivariate analysis 
were subsequently entered into a multivariate binary logistic 
regression model to determine predictors of  medication 
adherence and retention.
In addition, we also determined the socio-economic status 
(SES) index for each patient usingprincipal component 
analysis (PCA) and Stata statistical software version 10. The 
indicator variables used for PCA were (1) estimated monthly 
household incomeand (2) ownership of  ten household 
modern assets, including radio, plasma television, refrigerator, 
cable television, electric fan, air conditioner, motor vehicle, 
Table 1 Cont..
Table 2. Adherence and retention rates of PLHIV in Enugu
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washing machine, gas cooker and electric iron. Weights were 
assigned to the different variables and categories. The wealth 
index was calculated using the ‘balanced weight’ of  the 
variables. Each respondent was categorized into 2;  either a 
low or high SES index based on the wealth index score of  
their household.
Results
Table 1shows the socio-demographic characteristics of  our 
respondents; themean age of  respondents was 38.5±9.8 
years. The highest proportion of  respondents were aged 
30–39 years. The majority of  respondents were females 
(76.3%), which reflects the present demographics of  patients 
receiving HIV/AIDS care and treatment in Nigeria. Most 
Table 3. Predictors of adherence to ART among PLHIV in Enugu
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respondents were self-employed (74.2%) and there was a 
greater proportion of  respondents residing in rural areas 
(65.8%). More than 50% ofrespondents (497) had been 
on HAART for less than 4 years. Furthermore, there were 
more respondents on a first line regimen (80.4%) than 
those on a second line regimen (19.6%).When defined by 
a CD4 count <200 cells/µl, 43% of  our study participants 
(n=361) had AIDS. Our analysis identified that there was 
good adherence to anti-retroviral treatment in 89.5% (752) 
of  the respondents (Table 2). Approximately 87% (732) 
of  respondents were found to have adequate retention. 
Male respondents were twice as likely to adhere to their 
Table 4. Predictors of retention
    Chime et al; Malawi Medical Journal 31 (3): 202-211 September 2019             Predictors of adherence and retention for ART  208
https://dx.doi.org/10.4314/mmj.v31i3.7 
ART than their female counterparts though the difference 
in proportion was not found to be statistically significant 
(adjusted odds ratio [AOR]: 2.08; 95% confidence interval 
[CI]: 1.12–3.85) p=0.199 (Table 3). Respondents on 
HAART for more than 5 years were also twice as likelyto 
achieve adherence when compared with those who had 
taken HAART for less than 5 years and the difference in 
proportion was statistically significant (AOR: 1.92; 95% CI: 
1.17–3.16) p=0.023. Similarly, respondents who did not take 
alcohol had approximately four times the odds of  being 
adherent to their medications when compared to those 
who did use alcohol. There was a statistically significant 
difference in this proportion (AOR 3.67, 95% CI: 2.01–6.70) 
p<0.001. Those who did not consume traditional medicine 
were approximately three times more likely to have better 
adherence than those who did consume traditional medicine 
(AOR: 2.76; 95% CI: 1.33–5.73) p<0.001. Respondents with 
a baseline CD4 count >500cells/μl were approximately six 
times more likely to be adherent when compared with those 
having a baseline CD4 count < 200 cells/μl (AOR: 5.67; 95% 
CI:1.32–24.32). The difference in proportion was statistically 
significant (p=0.041). Participants who resided in urban 
areas were approximately twiceas likely to show adequate 
retainment as those who resided in rural areas (AOR: 
1.90; 95% CI: 1.17–3.06) This was statistically significant 
(p=0.005) (Table 4). Comparable proportion of  participants 
who had low SES had approximately one time the odds of  
being adequately retained than those with high SES (AOR: 
0.90; 95% CI: 0.62-1.46) P=0.085. The respondents with 
baseline CD4 <200 cells/ μl were three times less likely to be 
adequately retained when compared with their counterparts 
having baseline CD4 >500 cells/μl (AOR: 0.39; 95% CI: 
0.14-1.12) and the difference in proportions was found to be 
statistically significant (p=0.029). The commonest reasons 
for missing medication were being away from home (41.8%) 
and forgetfulness (35.0%). Other reasons included physical 
discomfort (6.8%), running out of  medication (12.6%), 
could not hide to take the drugs (2.4%) and fasting (1.4%) 
(Figure 1).
Discussion
Figure 1. Reasons for missed medications (N=294)
The WHO reports that approximately one-third of  patients 
suffering from HIV/AIDS take their medication as 
prescribed24.However, this remains a significant challenge for 
patients living in both developed and developing countries. 
The self-reported adherence to ART in this study was 89.5%, 
slightly higher than the 85.8% that was previously reported in 
Nnewi, another city in south-east Nigeria25. Seven years ago, 
when ART programs were only just being developed in our 
study area, the level of  adherence was as low as 75%5. This 
may possibly have been due to the lack of  drugsin several 
health facilities during this period of  time. Thus, inconsistent 
access to medications could have presented a challenge to the 
delivery system and unwittingly encouraged non-adherence. 
However, with enhanced availability and accessibility to 
medications, as well as the provision of  free ART services, 
it is evident that adherence has improved significantly in this 
region. The results of  our study were consistent with previous 
findings from some other developing African countries, 
where a high rate of  adherence (based on self-reporting)
has also been reported, including Ghana (86%)26,Rwanda 
(77%)27 and Ethiopia (95%)28. Interestingly, this finding is in 
direct contrast to a previous WHO report which stated that 
themean adherence rate to long-term therapy for chronic 
illnesses in developed countries was approximately 50%, and 
that in developing countries, the rates were even lower24.
We found that being away from home and forgetfulness were 
reported as the major reasons for missing medication; similar 
factors were noted in some other studies29,30. Other, less 
frequently reported reasons for missed doses included stock 
control problems for drugs, discomfort/side effects, being 
ashamed of  taking medication in front of  others and fasting. 
The retention of  PLHIV on ART in this study (87.1%) was 
higher than the 82.6% and 66.5% previously reported in private 
and public facilities in South-East Nigeria, respectively21.
Previous retrospective studies of  Nigeria, carried out over 
7 (2005–2012) and 5 years (2009–2013), showed retention 
ratesof  63% and 76.1%, respectively14,31. Based on these 
findings, we can therefore infer that although patients are 
still LTFU, and there is clear potential for the development 
and transmission of  drug-resistant strains of  HIV, there has 
been a progressive improvement in the rate of  retention 
in Nigeria. However, the approach of  measuring retention 
in these retrospective studies focused on only one or more 
visits to the clinic each yearand could therefore overestimate 
the level of  retention as patients LTFU would not 
have been included. A similar progressive increase in 
retention has been documented in Ethiopia, where 
the retention rate has risen from 77% (2004–2005) 
to 92% (2012–2013)13. These progressive increases in 
retention rates could be due to the massive scale-up of  
HIV services and recent intervention programs aimed 
at improving retention in these countries.
Our bivariate analyses revealed that there was a 
statistical association between adherence to medication 
and gender, the number of  years on HAART, alcohol 
intake, the intake of  traditional medicine and baseline 
CD4 cell count. The finding that men were more likely 
to adhere to their medication than women is a true 
reflection of  gender issues in sub-Saharan Africa as 
African men are generally seen to have more“free” 
time and money at their disposal than women32. This 
finding was similar to a previous study carried out 
in south-east Nigeria, which found that females were less 
adherent to their medications due to forgetfulness, poor 
communication and the side effects of  drugs19. Furthermore, 
due to cultural barriers, women in our study setting may have 
had difficulties disclosing their status, thus meaning that they 
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needto hide while taking their medications. 
Patients who have been on HAART for a longer duration 
would have been exposed to the relative advantages and 
disadvantages of  adhering to their medicationas they would 
have witnessed treatment failure and possibly the death of  
non-adherent patients. Poor adherence rates among those 
who have been on HAART for short durations could also be 
the result ofanti-retroviral-related toxicity experienced when 
the medication was first introduced. This significant finding 
implies that adherence improves over longer durations of  
treatment.Similar findings were described for Botswana, 
where patients who had been receiving ART for the shortest 
duration of  time (1–6 months) had the poorest adherence 
to medication33. However, a conflicting finding was reported 
for HIV-positive pregnant women in south-east Nigeria; in 
this particular cohort of  patients, there was a lower rate of  
adherence reported for those who had been on HAART 
for long periods of  time34. This finding was attributed to 
complacency, especially among long-term patients who 
saw clear improvements in theirphysical and psychological 
function. This may have reduced their motivation to adhere 
to anti-retroviral medications after delivery. Our study 
further showed that patients who took alcohol and traditional 
medicine showed poor adherence to their medications.The 
association between alcohol intake and adherence has been 
documented in previous studies35. In contrast to our present 
findings, drinking alcohol was not associated with non-
adherence to antiretroviral therapy in a study carried out in 
Ethiopia36. This inconsistency could represent socio-cultural 
differences in the two different study settings. Although 
the intake of  traditional concoctions has been reported as 
a barrier to ART adherence, PLHIV on anti-retrovirals in 
South Africa still ingest these concoctions, which are sourced 
from traditional healers, while adhering to their ART, as they 
are reported to act as an internal body cleanser37.
In most resource-limited countries of  Africa, where most 
of  the world’s HIV-infected people live, the diagnosis of  
HIV infection is often made during advanced stages when 
AIDS-defining illnesses begin to manifest38. It is therefore 
not surprising that a CD4 count <200 cells could predict 
adherence to medication in this study; 43% of  patients 
presented with a CD4 count <200 cells at baseline. 
Similarly, other studies have reported that patients with 
CD4 counts>200 cells at the beginning of  ART were at a 
higher risk of  non-adherence7,39. These patients probably 
deem themselves to be healthy and therefore decided not 
to carry on with their medications. Retaining PLHIV has 
the potential not only to limit health care costs but also to 
provide the opportunity to implement preventive health 
care interventions.This may promote behavioural changes in 
healthcare, thus leading to a reduction in HIV transmission 
and burden, thus leading to a general improvement in public 
health40.We found that the area of  residence was a significant 
predictor of  retention in our present study. Patients residing 
in rural areas might have difficulties accessing health facilities. 
This is because more health facilities offer HIV treatment 
services in urban areas than rural areas, thus making it 
difficult for those in rural areas to access care. Distance to 
the clinic, as well as travel times that exceed 2 hours due to 
bad roads, or financial constraints, have also been identified 
as major barriers to retention in previous studies14,40.
Conclusion
The rate of  adherence to medication and retention-in-care 
was higher in our study area than other studies conducted in 
Nigeria. Gender, the number of  years on HAART, alcohol 
intake and the intake of  traditional medicine predicted 
non-adherence to medication while residence in urban 
areas predicted retention. While some of  these factors are 
modifiable, others are not. Based on this study,we recommend 
that to achieve good adherence and adequate retention, 
programs and research should focus on interventions that 
can particularly improve adherence among females and lead 
to behavioural modifications whichcan reduce the intake of  
alcohol and traditional medications in the study area. These 
practices will invariably improve the adherence to ART in 
this region. Although the level of  adherence to medication 
among PLHIV is increasing insouth-east Nigeria, there is a 
need for sustained improvement to ensure optimal health 
outcomes.A decline in adherence has been projected in 
resource-limited settings as treatment access increases. 
Although the number of  available treatment facilities 
continues to increase in this setting, patients may continue to 
avoid accessing care from facilities within their communities 
because of  stigma. Consequently, the scale-up of  treatment 
facilities must be coupled with social support from the 
community. Our findings also support the need to evaluate 
access to health facilities based on their localities to ascertain 
measures to specifically support patients in rural settings.
Limitations
There is no gold standard for measuring adherence. In the 
present study, we based adherence only by analysing the 
self-reporting of  missed doses over a period of  28 days. 
It is possible that this may be affected by recall bias and 
overestimation7.The use of  more objective measures, such 
as a microelectronic monitoring system for pill counts, 
would have provided a more comprehensive assessment of  
adherence than self-reporting. However, a simple self-report 
adherence questionnaire, such as the one used in this study, 
has previously been reported to provide a profound degree 
of  non-adherence that predicts viral rebound and is almost 
always reliable7.Finally, the exclusion of  patients who have 
been on HAART for less than a year, as well as patients in 
HIV clinical stage 3 and 4, may also affect the generalization 
of  the findings of  this study.
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